SI-12 is a small molecule inhibitor of SRC-3 closely related to SI-2, and to further enhance the efficacy of SI-12 as an anti-cancer therapeutic, we sought to explore a discovery-based approach to identify gene targets that would have synthetic lethality under the pressure of SRC-3 inhibition. This evidence concerns the gene NCOA3 and cancer.